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Abstract
Background: Hepatitis B virus (HBV) replication has been reported to be involved in many
extrahepatic viral disorders; however, the mechanism by which HBV is trans-infected into
extrahepatic tissues such as HBV associated myocarditis remains largely unknown.
Results: In this study, we showed that human cord blood endothelial progenitor cells (EPCs), but
not human umbilical vein endothelial cells (HUVECs) could be effectively infected by uptake of HBV
in vitro. Exposure of EPCs with HBV resulted in HBV DNA and viral particles were detected in
EPCs at day 3 after HBV challenge, which were peaked around day 7 and declined in 3 weeks.
Consistently, HBV envelope surface and core antigens were first detected in EPCs at day 3 after
virus challenge and were retained to be detectable for 3 weeks. In contrast, HBV covalently closed
circular DNA was not detected in EPCs at any time after virus challenge. Intravenous
transplantation of HBV-treated EPCs into myocardial infarction and acute renal ischemia mouse
model resulted in incorporation of HBV into injured heart, lung, and renal capillary endothelial
tissues.
Conclusion: These results strongly support that EPCs serve as virus carrier mediating HBV trans-
infection into the injured endothelial tissues. The findings might provide a novel mechanism for
HBV-associated myocarditis and other HBV-related extrahepatic diseases as well.
Background
As many as 20% of patients with hepatitis B virus (HBV)
infection experience a spectrum of extrahepatic disorders
that includes dermatologic disease, polyarthralgias and
arthritis, glomerulonephritis, polymyositis, aplastic ane-
mia, neuropathy, vasculitis and myocarditis [1-3]. Recent
studies revealed that the virus has extensive reservoirs of
extrahepatic replication [4]. HBV proteins and nucleic
acids have been found in a number of non-hepatic tissues
including lymph nodes, spleen, bone marrow, kidney,
colon, stomach, periadrenal ganglia, skin, thyroid, pan-
creas, testis, ovaries, brain, heart and lung tissue [5-8]. It is
likely that many different cell types such as endothelial
cells, epithelial cells, neurons, macrophages, bone mar-
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row cells, peripheral blood mononuclear cells and poly-
morph nuclear leukocytes are permissive for HBV
replication in humans [4,7,9-11]. Recently, HBV replica-
tion was found in damaged endothelial tissues of patients
with extrahepatic disease [12], which indicates that
endothelial tissues may be one of the tropism tissues
infected by HBV in extrahepatic disease. However, in con-
trast, several other studies have demonstrated that the
HBV is not replicated in peripheral blood mononuclear
cells (PBMCs) [13], endothelial cells [14], and lymphatic
tissues [15]. Therefore, whether HBV could be replicated
in extrahepatic tissues remains controversial.
Endothelial progenitor cells (EPCs) are primitive cells
made in the bone marrow that can enter the bloodstream
and go to areas of blood vessel injury to help repair the
damage. It should be pointed out that EPCs not only exist
in adult bone marrow, but also exist in blood circulation
and peripheral cord blood [16,17]. Emerging evidence
suggests that EPCs are able to differentiate into mature
endothelial cells, contribute to neovascularization and
reendothelialization during both embryonic and postna-
tal physiological processes [16-21]. Despite bone marrow-
derived cells including hematopoetic stem cells and
peripheral blood mononuclear cells were recently shown
to support HBV replication, the subset of these cells such
as EPCs has not been explored. It is possible that EPCs are
also permissive for HBV uptake or replication. Therefore,
in this study we tested whether EPCs from human umbil-
ical cord blood can be infected with HBV in vitro. The data
provided in this study show for the first time that EPCs
can be effectively infected by uptake of HBV in vitro.
Using myocardial infarction (MI) mouse model induced
by ligation of coronary artery and acute renal ischemia
mouse model induced by unilateral renal artery clamping,
we could show that transplantation of EPCs with HBV in
mice leads to HBV tans-infection into injured extrahepatic
endothelial tissues in heart, lung, and kidney through the
processes of EPCs recruitment. Taken together, our results
suggest that the harboring of HBV in EPCs could serve as
one of extrahepatic infective sources, which might point
to a novel role of EPCs in mediating HBV associated myo-
carditis and other HBV-related extrahepatic diseases as
well.
Results
Characterization of EPCs
EPCs showed a spindle-shaped, endothelial cell-like mor-
phology after 7 days culture in Medium-199 (Fig. 1A).
EPCs were capable of uptaking DiI-ac-LDL (Fig. 1B).
Immunohistochemistry showed that the cells were posi-
tive for endothelial cell surface markers such as vWF and
CD31 expression (Fig. 1C and 1D). Furthermore, flow
cytometric analysis showed that 81.7 ± 12.2% of the cells
were positive for CD34, 37.5 ± 10.6% were positive for
CD133 and 48.2 ± 8.1% positive for KDR expression (Fig.
1E and 1F). In addition, EPCs were capable of forming
capillary tubule-like structures on Matrigel (Fig. 2A). In
contrast to EPCs, HUVECs grew close to one another in
parallel arrays and were positive for vWF and CD31
expression, and contained cytoplasmic inclusions
(Weibel-Palade bodies) characteristic of in situ endothe-
lial cells (data not shown).
HBV infection had no effect on angiogenic capacity of EPC
The effect of HBV on endothelial network formation of
EPCs was further determined in vitro tubule formation
assay. HBV-treated EPCs were observed for initiation and
maintenance of capillary tubule-like structures over 3 days
(Fig. 2). The capillary-like structures were similar between
mock-treated and Virus-treated EPCs (19.3 ± 1.78 for
mock-treated vs.19.5 ± 2.31 for virus-treat, n = 20, p >
0.05). The results suggested that HBV infection may not
affect EPCs potential function on tubulogenesis and ang-
iogenesis.
EPC is a target for HBV infection
To determine whether EPC could be a target for HBV
infection, cells were immediately exposed to either HBV
positive serum (virus-treated) or non-virus control serum
(mock-treated) after initial seeding. HBcAg was first
detectable at day 3 after infection with HBV (Fig. 3A), and
retained to be detectable for 3 weeks (data not shown).
HBcAg was predominantly found in the cytoplasm of
infected cells (Fig. 3B). Flow cytometric analysis showed
that 33.5 ± 9.1% (n = 5) of EPCs were positive for HBsAg
(Fig. 3G), and 40 ± 17.3% (n = 5) of EPCs were positive
for HBcAg (Fig. 3H), respectively. As expected, no HBsAg
and HBcAg expression found in mock-treated EPCs (Fig.
3D and 3E) and HUVECs (Fig. 3F). It is worth noting that
there was no HBcAg expression observed in HUVECs at
any time points after exposure to HBV by either immuno-
histochemistry (Fig. 3C) or by flow cytometric analysis
(Fig. 3I).
The infection of EPC with HBV was also evidenced by
virus DNA detection. Seven days after infection of cells
with virus positive serum (108 copies of HBV DNA/106
cells), we could detected about 6.8 × 105 copies of HBV
DNA/106 cells in the primary EPC culture (Fig. 4A). How-
ever, further cultivation of cells resulted in a rapid
decrease in HBV DNA in EPCs, which was completely dis-
appeared in 4 weeks after virus challenge (Fig. 4A). In con-
trast to EPC, there was only lower copies of HBV DNA (2.6
× 103 copies/106 cells) could be detected in the primary
HUVECs culture, and no any trace of virus DNA was
detected in HUVECs after first passage (Fig. 4B). These
results support that EPC rather than HUVEC is more sus-
ceptible to HBV uptake and infection. Significantly, noVirology Journal 2007, 4:36 http://www.virologyj.com/content/4/1/36
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Characterization of EPC Figure 1
Characterization of EPC. Isolated EPCs were visualized by phase-contrast microscope (A 400 ×), and DiI-Ac-LDL uptake 
was analyzed by fluorescent microscope (B 100 ×). The cells were further analyzed by immunostaining with anti-CD31(C 200 
×) and vWF antibodies(D 200 ×), or by flow cytometry with anti-KDR (E) and CD34/CD133 antibodies (F).
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HBV cccDNA could be detected in EPC at any time after
HBV infection (data not shown).
Using transmission electron microscopic analysis, HBV-
like particles could be detected in the virus-treated EPCs.
As shown in Fig. 5A–5C, HBV particles were roughly
spherical with a variable diameter of 50 to 200 nm. Many
of them with a diameter of 80 nm, and some of them
showed 80 nm width and 200 nm length like filaments of
HBsAg. These particles were localized exclusively in cyto-
plasm but not in rough endoplasmic reticulum (RER) and
nucleus. The virus particles were peaked at day 4–7 after
infection, and were reduced to half at day 14. Only few
virus particles were observed at day 21, and they were
completely disappeared after day 28 (Fig. 4C). No virus
particle could be detected in mock treated-EPCs (Fig. 5D)
and in virus-treated HUVECs (Fig. 5E–5F), indicating that
infection of HBV is a predominant phenomenon of EPCs.
It is worth noting that there were more vesicles and RERs
in the cytoplasm of HUVECs (Fig. 5E and 5F) when com-
pared to EPCs (Fig. 5D).
HBV is trans-infected into heart, lung, and kidney through 
the process of EPC recruitment
Finally, we examined whether HBV can be transmitted to
animal tissues by in vivo transplantation of EPCs into MI
mouse model. Our data showed HBV-treated EPCs had a
higher capacity to induce neovascularization. Both HBsAg
and HBcAg were observed in the interstitial tissues (Fig.
6C and 6D) and capillaries (Fig. 6E), in peri-infarct areas
after cell transplantation for 2 weeks. Neither HBcAg nor
HBsAg was found in mouse heart tissues transplanted
with mock-treated EPCs (Fig. 6A and 6B).
To further address whether the virus-positive cells in the
tissues are derived from human EPCs, a human HLA-ABC
antibody was used to identify the human major histocom-
patibility complex (MHC). As expected, HBcAg was not
found in mouse heart tissues transplanted with mock-
treated EPCs (Fig. 6G). However, in the HBV-treated EPCs
transplantation, HBcAg antigen was exclusively co-
expressed with human MHC positive cells (stained by
HLA-ABC) in the intramyocardial capillaries in the peri-
infarct area (Fig. 6I and 6J). No HBV DNA was found in
blood when mice were transplanted with HBV-treated
EPCs, and no HBV antigens were found in heart tissues in
both MI and sham-operated mice received only virus
transplantation (data not shown). These results clear indi-
cated that the HBV positive cells found in the injured cap-
illary endothelial tissues were differentiated from the
transplanted human EPCs.
Recent evidence shows that EPCs not only participate in
tissue repair processe in cardiovascular disorders [16-19],
but are also able to mobilize and homing into injured
renal medullopapillary region in response to renal injury
[20] and injured lungs in elastase-induced lung injury
[21]. It would be interesting to investigate whether HBV
virus-infected EPCs could be recruited into these injured
sites where they were further differentiated to capillary
Effect of HBV infection on tubules formation of EPCs Figure 2
Effect of HBV infection on tubules formation of EPCs. Matrigel was polymerized on 96-well plates, and 1 × 104 of EPCs 
were plated in Medium 199 containing either 10% normal control serum (mock-treated, A) or10% HBV-positive serum (HBV-
treated, B), and incubated at 37°C for 72 hrs. The tubules formation was visualized by an inverted microscope. Magnification 
for panel A, × 400; for panel B, × 600.Virology Journal 2007, 4:36 http://www.virologyj.com/content/4/1/36
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Expression of HBsAg and HBcAg antigens in EPCs Figure 3
Expression of HBsAg and HBcAg antigens in EPCs. EPCs (A, B, D, E, G, and H) and HUVECs (C, F, and I) were co-cul-
tured with HBV (A-C, and G-I) for 4 days, washed and maintained for another 3 days or without virus (D-F) for 7 days. The 
cells were either immunostained with anti-HBcAg antibody (A and C, × 200; and B, × 600), or analyzed by flow cytometry with 
anti-HBsAg (D and G) and anti-HBcAg antibodies (E, F, H and I).
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endothelial cells. Since the secondary lung and kidney
injury was a frequent complication of acute or chronic MI
[22-24], we first thought to check whether the HBV anti-
gens could be detected in the injured lung tissues. Both
HBcAg and HBsAg were detected in interstitium of lung
(Fig. 7C and 7D) after 2 weeks transplantation with HBV-
treated EPCs in MI mice. As expected, no HBV virus anti-
gens were detected in lung tissues when MI mice trans-
planted with HBV-positive serum alone (containing 2.5 ×
106 copies of HBV DNA) (Fig. 7A and 7B). We then further
examined the HBV antigen expression in the injured kid-
ney tissues. Similarly, HBV antigens were detected in renal
glomerular vascular endothelium in MI mice with (Fig.
7G and 7H) or without unilateral renal artery clamping
(data not shown). No HBV virus antigens were detected in
kidney when mice transplanted with HBV-positive serum
alone (Fig. 7C and 7D). These data strongly suggested that
EPCs may play a critical role in mediating trans-infection
of HBV into extrohepatic tissues via the process of EPCs
recruitment.
Discussion
HBV proteins and nucleic acids detected in extrahepatic
tissues are tropism in endothelial tissues including
endothelium, epithelium, and macrophages [25,26]. Sev-
eral studies have demonstrated that HBV DNA or HBV
antigen was detected in PBMCs [27] or bone marrow cells
[11,28,29], suggesting that these cells could be infected
with HBV, while others have demonstrated that the HBV
is not replicated in PBMCs [13]. It is clear that the evi-
dence for replication of the HBV at extrahepatic sites is
controversial or incomplete, and these sites are not usu-
ally considered in discussions of viral reproduction and
pathogenesis. In this study, we demonstrated in the first
time that EPC is a predominant target for HBV infection
in vitro. The virus particles detected in this study have the
diameters ranged from 50 nm to 200 nm, and most of
which are about 80 nm. Similarly, several previous studies
have reported 80 nm HBV virus particles in liver biopsy
and 70 nm HBV virus particles in kidney biopsy by elec-
tron microscopy [30,31]. In contrast, Kendrey et al.
reported a virus particle with 80 nm diameter that might
be another virus infection [30]. Significantly, the number
of viral particles and copies of HBV DNA detected in the
virus-treated EPCs were increased in 7 days and were rap-
idly decreased afterwards in a time-dependent manner
(Fig. 4A and 4C). Our results are consistent with another
study on hepatitis B antigen in bone marrow cells by Chai
et al. [28]. The reason for short life of viral particles and
HBV DNA in EPCs is not clear. Several previous studies
have reported that HBV replicates in ER and vesicle
[32,33]. In our study, EPCs were shown to be short of
rough endoplasmic reticulum (RER) and vesicles, which
may argue that HBV was unable to replicate in EPCs. Con-
sistently, the negative results for HBV cccDNA detection in
the virus-exposed cells further support EPCs were the tar-
gets preferable for HBV uptake rather than viral replica-
tion.
Recently, Murohara et al. [34] found that cord blood
derived EPC transplantation quantitatively augmented
neovascularization and blood flow in the ischemic hind
limb. Ricousse-Roussanne et al. [35] demonstrated pro-
genitors of both endothelial cells and smooth muscle cells
Time dependent expression of HBV in EPCs Figure 4
Time dependent expression of HBV in EPCs. Detection of HBV DNA and HBV particles in EPCs (A and C) and HUVECs 
(B) by qRT-PCR analysis (A and B) and by transmission electron microscopy (C) at various times as indicated. The viral parti-
cles were calculated under transmission electron microscopy (× 20,000) from 5 different fields. D = Day.Virology Journal 2007, 4:36 http://www.virologyj.com/content/4/1/36
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Detection of HBV viral particles in EPCs Figure 5
Detection of HBV viral particles in EPCs. HBV-treated (A, B, and C) or mock-treated EPCs (D) or HBV-treated 
HUVECs (E and F) were cultured in Medium 199 for 7 days and the cells were analyzed by transmission electron microscope. 
Arrows indicate the virus particles with a diameter of 80 nm in B and C, vesicle in E, and rough endoplasmic reticulum (RER) in 
F. Bars are 500 nm in A, E, and F; 200 nm in B; 100 nm in C; and 1 μm in D.
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Detection of HBV antigens in mouse heart tissues Figure 6
Detection of HBV antigens in mouse heart tissues. Two weeks after cell transplantation, hearts were harvested, immu-
nostained with anti-HBcAg (A, C, and E) and anti-HBsAg (B and D). Myocardial interstitium (A-D) and intra-myocardial capil-
laries (E) in the peri-infarct area were shown. Hematoxylin and eosin (H&E) staining of heart tissue after 2 weeks MI-induction 
revealed a clear infract area (F). Magnification for panels B and D, × 800; for panels A, C and E, × 400; and for panel F, × 40. In 
addition, hearts were double immunostained with HBcAg (G and I) and human HLA-ABC (H and J) 3 weeks after cell trans-
plantation as described in "Materials and Methods". Intra-myocardial capillaries in the peri-infarct area were shown. Magnifica-
tion × 400. Mice transplantated either with mock-treated EPCs (A, B, G, and H) or with HBV-treated EPCs (C-E, I and J) were 
indicated. Results are representative of at least three independent experiments.
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Detection of HBV antigens in mouse lung and kidney tissues Figure 7
Detection of HBV antigens in mouse lung and kidney tissues. Lung interstitium (A-D) in MI mice and renal glomerular 
vascular endothelium (E-H) in MI mice with acute renal ischemia were immunostained with anti-HBcAg (A, C, E and G) and 
anti-HBsAg (B, D, F and H) after 2 weeks of cell transplantation. Magnification × 800. Mice transplantated either with HBV 
alone (A, B, E and F) or with HBV-treated EPCs (C, D, G and H) were indicated. Results are representative of at least three 
independent experiments.
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were present in cord blood and that they could differenti-
ate into matured endothelial cells and smooth muscle
cells. In our study, EPCs derived from cord blood are char-
acterized by the expression of the early hematopoietic
stem cell markers CD34, CD133 and VEGFR-2 (KDR),
and can differentiate into cells that display a classical
endothelial cell morphology and characteristics, such as
the expression of von Willebrand factor and CD31, and
the capacity to uptake acetylated low-density lipoprotein.
It is worth noting that the angiogenic property of EPCs
was also not affected by in vitro HBV infection, indicating
that the potential role of EPCs in neovascularization may
not be impaired by virus uptake.
EPC transplantation has been shown to induce new vessel
formation in ischemic myocardium [36-38] and to accel-
erate re-endothelialization of injured vessels and pros-
thetic vascular grafts in humans and in various animal
models [39,40]. Our data from transplantation of HBV-
treated EPCs in MI-mouse models and in the acute renal
ischemia mouse models revealed that EPCs together with
HBV were able to incorporate not only into injured
intramyocardial capillary and interstitial tissues in the
peri-infarct areas, but also into lung and kidney tissues.
Our findings support the hypothesis that HBV incorpora-
tion into the vascular endothelium is due presumably to
the fact that EPCs is capable of uptaking and transporting
the virus into the damaged tissues via the process of hom-
ing and transdifferentiation.
The pathogenesis of the HBV-related extrahepatic disor-
ders is poorly understood, several mechanisms have been
proposed [1,2]. These include the deposition of circulat-
ing hepatitis B antigen-antibody complexes in extrahe-
patic tissues; the local induction of immune complex
formation in extrahepatic tissues; viral induction of host
autoantibodies reactive with extrahepatic tissues; and ext-
rahepatic viral replication. It is known that the timing of
onset of most extrahepatic disease coincides with immune
complex formation, which suggests a major role for
immune complexes in disease formation with immune
and viral consequences in the extrahepatic organs. Theo-
retically, it would be also possible that the extrahepatic tis-
sue injury caused by immune complex formation at the
time of acute (or chronic) infection may trigger the activa-
tion of tissue repairing process, which leads to HBV-
infected EPCs and/or other bone marrow-derived stem
cells recruited into the injured tissues. However, this must
be tested experimentally using acute (or chronic) hepatitis
animal models. An alternative mechanism by which both
immune complexes and HBV replication within the
endothelium combine to promote extrahepatic disease
has been recently proposed [12]. However, how the
immune complexes-mediated tissue injured occurs, and
the mechanism by which allows entry of HBV into extra-
hepatic tissues has not been established. Our study clearly
demonstrates that EPCs are capable of uptaking active
HBV virus that facilitates virus incorporation into injured
endothelial tissues. These results are supportive of a novel
role for EPCs in mediating HBV-related extrahepatic disor-
ders, which may account for most clinic transient or
asymptomatic HBV-related extrahepatic manifestations
such as vasculitis, myocarditis, glomerulonephritis, and
polymyositis. However, how re-colonization of HBV by
EPC uptake results in the extrahepatic disorders still
remains to be elucidated. Since our data do not support
viral replication in EPCs, it is difficult to envision the ext-
rahepatic manifestations by HBV resulting from direct
uptake of virus. Nevertheless, it should be pointed out
that our results can not rule out the possibility of viral rep-
lication in the regenerated endothelial cells that differen-
tiated from HBV-infected EPCs. It is possible that virus
uptake in EPCs allows virus entry into the injured tissues,
which would in turn mediate a secondary infection and/
or a local immune complex formation in the extrahepatic
tissues via the activation of tissue repairing machinery.
Given the complexity of extrahepatic disorders, further
studies are required to address (i) whether re-colonization
or incorporation of HBV in EPCs and in the extrahepatic
endothelial cells could be reactivated to infect the neigh-
boring cells and tissues; (ii) whether and how the incor-
poration of virus into the extrahepatic endothelium has
pathological consequence on the injured organs.
Conclusion
In conclusion, our results demonstrate that HBV can be
effectively uptaken into EPCs in vitro. HBV uptake had no
inhibitory effects on EPCs angiogenic potential. Trans-
plantation of EPCs into MI and acute renal ischemia
mouse models revealed that EPCs can serve as a virus res-
ervoir harboring and transporting HBV to the injured
endothelial tissues. The above data support to a novel role
of EPCs in mediating virus associated extrahepatic dis-
eases including virus relevant tumor diseases.
Methods
Chemicals and antibodies
Chemicals and antibodies were as follows: 1,1'-dioctade-
cyl-3,3,3',3'-tetramethylindocarbocyanine-labeled
acetylated LDL (DiI-acLDL, Molecular Probe); fetal calf
serum (Hyclone); VEGF, and FITC-conjugated goat anti-
mouse IgG antibody (Cytolab); Medium 199, bovine
brain extract, and goat polyclonal anti-von Willebrand
factor (vWF) (Sigma); FITC-conjugated mouse mono-
clonal anti-human CD34 (Immunotech); mouse mono-
clonal anti-VEGF receptor 2 (KDR) and FITC-conjugated
goat polyclonal anti-HBsAg (Ad/Ay) (abcam); R-Phyco-
erythrin (PE)-conjugated mouse monoclonal anti-human
CD133 (Miltenyi Biotec, Bergisch Gladbach, Germany);
mouse monoclonal anti-HBcAg (ayw, USBio); goat poly-Virology Journal 2007, 4:36 http://www.virologyj.com/content/4/1/36
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clonal anti-CD31 antibody (Santa Cruz Biotechnology);
mouse monoclonal anti-hepatitis B virus surface antigen
(HBsAg) (Dako, Denmark), rabbit polyclonal anti-hepati-
tis B core antigen (HBcAg) (Maoxin, China); anti-human
leukocyte antigen HLA-ABC (Chemicon); goat anti-rabbit
IgG Texas red conjugate (Calbiochem); horseradish per-
oxidase-conjugated anti-goat IgG (Sigma); epoxy resin
(TAAB 812; Emmer Green, Reading, England); DAB stain-
ing kits (Wuhan BoShiDe Biological Engineering Ltd.);
cyclosporin A liquid (Fujian China Kerui Medicine Co.
Ltd.); OCT medium (Sakura, USA). All other chemicals
were of the highest grade commercially available.
Preparation of virus
HBV-positive serum samples (≥ 1 × 106 copies of HBV
DNA/mL) were obtained from the patients with chronic
HBV infection. Sera were filtered through 0.22-um pore-
sized filters and stored at -20°C. As a normal control,
serum specimens were obtained from healthy human vol-
unteers with no history of HBV exposure and lacked sero-
logic evidence of previous or current HBV infection.
Isolation and cultivation of human EPCs
Human cord blood was collected from umbilical vein
from healthy newborn donors by a protocol approved by
the ethical committee of the Medical Faculty of Nanjing
medical University. Mononuclear cells (MNCs) were iso-
lated by density-gradient centrifugation using 1.077 g/mL
Histopaque solution. Human umbilical vein endothelial
cells (HUVECs) were isolated according to the method of
Jaffe et al. [41]. Both MNCs and HUVECs with a density of
2 × 106 cells/cm2 were plated on fibronectin-coated dishes
(2 μg/cm2, Chemicon) and cultured in Medium 199 sup-
plemented with 20% fetal calf serum, 12 μg/mL of bovine
brain extract, 10 ng/mL of VEGF, penicillin (100 U/mL),
and streptomycin (100 μg/mL).
Infection of EPCs with HBV
For cell infection, freshly isolated MNCs were cultured in
Medium 199 containing either 10% of HBV-positive
(virus-treated) or normal control serum (mock-treated)
for the first 4 days. After 4 days culture, free virus and non-
adherent cells were removed and fresh media were
replaced. The cells were further cultured for additional 3
days. The numbers of spindle-shaped and attached cells
and cell clusters were counted under microscope at day 4
and day 7 of culture. Five randomly selected microscopic
fields were evaluated and mean numbers of attached cells
and cell clusters were calculated.
HBV DNA extraction and quantification
Approximately 106 EPCs and HUVECs were treated with
proteinase K in the presence of sodium dodecyl sulfate,
and HBV DNA was then purified by DNA extraction kit
(Tiangen, Beijing) according to the manufacturer's proto-
col. HBV DNA contents were determined by quantitative
real-time polymerase chain reaction (qRT-PCR) using
HBV fluorescence quantitative PCR diagnostic kit (Daan-
gene, China). Primers used for HBV DNA detection were:
5'-ATCCTGCTGCTATGCCTCATCTT-3' (forward), and 5'-
ACAGTGGGGAAAGCCCTACGAA-3' (reverse). The probe
used was 5'-TGGCTAGTTTACTAGTGCCATTTTG-3'. HBV
covalently closed circular DNA (cccDNA) quantification
was performed as described previously [42]. The primers
used for HBV cccDNA quantification were: 5'-ACTCTT-
GGACTCBCAGCAATG-3' (forward), and 5'-CTTTATACG-
GGTCAATGTCCA-3' (reverse). The probe used was 5'-
CTTTTTCACCTCTGCCTAATCAT CTCWTGTTCA-3'. A
plasmid containing Chinese HBV genome (pHBV-adr) (a
gift from Professor Yuan Wang) was used as positive con-
trol.
Histology, immunohistochemistry, and 
immunofluorescence
Isolated mouse tissues were fixed in 10% formaldehyde,
embedded with paraffin and cut into 4 μm thick sections.
The tissue sections were then rinsed with PBS for 3 times,
blocked with 5% horse serum in PBS at room temperature
for 30 min. For HBV antigens detection, the sections were
incubated with mouse monoclonal anti-HBsAg and rabbit
polyclonal anti-HBcAg, and were detected by DAB stain-
ing kit according to the manufacturer's protocol. For
immunofluorescent double-staining, the sections were
incubated with rabbit polyclonal anti-HBcAg antibody at
room temperature for 1 hr, followed by anti-HLA-ABC for
a further 1 h. Sections were then extensively washed and
incubated with Texas Red-conjugated anti-rabbit IgG and
FITC-conjugated anti-mouse IgG (both 1:100 dilution) at
room temperature for 30 min. After extensive washing,
the sections were mounted and visualized using fluores-
cent microscope (Nikon, Japan).
For detection of endothelial cell surface markers, the cells
were plated on 6-well chamber slides for 7 days, and then
washed and fixed with acetone at 4°C for 10 min. The
cells were blocked with 5% horde serum for 30 min and
incubated overnight at 4°C in 1:100 dilutions of goat pol-
yclonal anti-vWF and CD31 antibodies, followed by incu-
bation with horseradish peroxidase-conjugated anti-goat
IgG for additional 30 min. The slides were visualized with
DAB-based color development. For detection of HBV anti-
gens, the cells were incubated with mouse monoclonal
anti-HBsAg and rabbit polyclonal anti-HBcAg, and were
detected by DAB staining kit according to the manufac-
turer's protocol.
Fluorescent microscopy and electron microscopy
Fluorescent chemical detection of EPCs was performed on
attached cells after 7 days in culture. Direct fluorescent
staining was used to detect DiI-acLDL of the cells. Briefly,Virology Journal 2007, 4:36 http://www.virologyj.com/content/4/1/36
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adherent cells were washed with fresh medium and incu-
bated with 10 μg/mL of DiI-acLDL at 37°C for 4 hrs. Cells
were then fixed in 2% paraformaldehyde for 10 min and
the number of EPCs was examined under fluorescent
microscope (Nikon 120). For electron microscopy analy-
sis, cells were scraped and first fixed in 2.5% glutaralde-
hyde for 3 hrs, followed by 1% osmium tetroxide in 100
mM phosphate buffer for additional 30 min. After dehy-
dration, tissues were embedded in epoxy resin. Ultrathin
sections were stained with uranyl acetate and lead citrate,
and were visualized under transmission electron micro-
scope (JEOL 1010, Japan).
Fluorescence activated cell sorting (FACS) analysis
For EPC characterization, cells were detached with 1 mM
EDTA followed by repeated gentle flushing through a
pipette tip. Cells (2 × 105) were incubated for 30 min at
4°C with FITC-conjugated mouse monoclonal anti-
human CD34, mouse monoclonal anti-VEGF receptor 2
(KDR), and R-Phycoerythrin (PE)-conjugated mouse
monoclonal anti-human CD133 antibodies. After exten-
sive washing, the cells were incubated with FITC-conju-
gated goat anti-mouse IgG antibody for additional 30
min. FITC-conjugated isotype-identical IgG (Caltag Lab)
served as negative controls. Flow cytometric analyses were
performed by FACScan and Cell Quest software (Becton,
Dickinson). Each analysis included at least 50 events.
For viral proteins detection, cells (1 × 106) were fixed and
permeabilized as described previously [43], followed by
incubation with FITC-conjugated goat polyclonal anti-
HBsAg and mouse anti-HBcAg at room temperature for 20
min. Cells were then washed with PBS and incubated with
FITC-conjugated goat anti-mouse IgG antibody at room
temperature for additional 20 min. After washing, the
cells were resuspended in 0.3 ml of PBS and analyzed by
FACS.
In vitro tubule formation assay
In vitro tubule formation assay was performed with In
Vitro Angiogenesis Assay Kit (Chemicon) according to the
manufacturer's instructions. Briefly, ECMatrix™ solution
was thawed on ice overnight then mixed with 10 × ECMa-
trix™ diluents and placed in a 96-well tissue culture plate
at 37°C for 1 h to allow the matrix solution to solidify.
Cells were plated (10,000 cells/well) on top of the solidi-
fied matrix solution, and were grown with HBV positive
serum or normal control as described above for 3 days.
Tubule formation was determined under an inverted light
microscope at 200× magnification. Tubule formation was
defined as a structure exhibiting a length four times longer
than its width. Five independent fields were assessed and
the average numbers of tubule branch points were deter-
mined.
Induction of myocardial infarction (MI) and acute renal 
ischemia
Male Sprague & Dawley mice weighing 150 to 250 g were
used (Nanjing Medical University Laboratories). Mice
were anesthetized with Ketamine 100 mg/kg and were
ventilated with 100% oxygen using a rodent ventilator
(Nanjing Medical Apparatus, Inc). The chest was opened,
a 6-0 silk suture was passed with a tapered needle under
the left anterior descending coronary artery 1 to 2 mm
from the tip of the left atrium, and the two ends of the
suture were tied to induce MI. In some experiments, mice
were subjected to unilateral renal artery clamping for 25
min after induction of MI. Sham-operated mice received
the same procedure except left anterior descending liga-
tion and unilateral renal artery clamping.
Transplantation of EPCs in mice
Two and a half million human EPCs that cultured in
Medium 199 containing 10% of HBV-positive serum for 4
days and changed Medium 199 containing 10% of HBV-
positive serum for another 3 days were injected through
the testicle vein of 15 mice 4 hrs after MI induction.
Cyclosporin A was administrated 24 hrs before the opera-
tion to suppress immune rejection. All experimental ani-
mals were given cyclosporin A at dosage of 10 mg/kg/day
during the experiments. The hearts were harvested at 1
week (n = 3), 2 weeks (n = 3), 3 weeks (n = 3) and 4 weeks
(n = 3) after cell transplantation. The lungs and kidneys
were harvested at 2 weeks (n = 3). Another group of 6
mice with MI surgical manipulation (n = 3) or sham sur-
gery (n = 3) was injected with the same number of non
viral infected EPCs (normal intervened) through the testi-
cle vein and killed at 2 weeks or 4 weeks after transplanta-
tion.
Tissue harvesting
Hearts, lungs, and kidneys were removed. Half of each
was immerged in 10% paraformaldehyde and embedded
in paraffin. Another half was embedded in OCT medium
followed by snap frozen in liquid nitrogen, and stored at
-80°C before analysis. Mouse bloods were also collected
and stored at -20°C for detecting HBV DNA by PCR.
Statistical analysis
All values are presented as mean standard error. All data
were subjected to unpaired Student's t-test for comparison
between two means. P values < 0.05 were considered to be
statistically significant.
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